BACKGROUND: No pharmacotherapies have been shown to increase long-term (> or = 6 months) tobacco abstinence rates among smokeless tobacco (ST) users. Bupropion SR has demonstrated potential efficacy for ST users in pilot studies. We conducted a multicenter, randomized, double-blind, placebo-controlled, clinical trial to assess the efficacy and safety of bupropion SR for tobacco abstinence among ST users. METHODS:Adult ST users were randomized to bupropion SR titrated to 150 mg twice daily (N=113) or placebo (N=112) for 12 weeks plus behavioral intervention. The primary endpoint was the 7-day point-prevalence tobacco abstinence rate at week 12. Secondary outcomes included prolonged and continuous tobacco abstinence rates, craving and nicotine withdrawal, and weight gain. RESULTS: The 7-day point-prevalence tobacco abstinence rates did not differ between bupropion SR and placebo at the end treatment (53.1% versus 46.4%; odds ratio (OR) 1.3; p=0.301). The 7-day point-prevalence abstinence did not differ at weeks 24 and 52. The prolonged and continuous tobacco abstinence rates did not differ at weeks 12, 24, and 52. A time-by-treatment interaction was observed in craving over time with greater decreases in the bupropion SR group. At 12 weeks, the mean (+/-S.D.) weight change from baseline among abstinent subjects was an increase of 1.7 (+/-2.9)kg for the bupropion SR group compared to 3.2 (+/-2.7)kg for placebo (p=0.005). CONCLUSIONS:Bupropion SR did not significantly increase tobacco abstinence rates among ST users, but it significantly decreased craving and weight gain over the treatment period.
RCT Entities:
BACKGROUND: No pharmacotherapies have been shown to increase long-term (> or = 6 months) tobacco abstinence rates among smokeless tobacco (ST) users. Bupropion SR has demonstrated potential efficacy for ST users in pilot studies. We conducted a multicenter, randomized, double-blind, placebo-controlled, clinical trial to assess the efficacy and safety of bupropion SR for tobacco abstinence among ST users. METHODS: Adult ST users were randomized to bupropion SR titrated to 150 mg twice daily (N=113) or placebo (N=112) for 12 weeks plus behavioral intervention. The primary endpoint was the 7-day point-prevalence tobacco abstinence rate at week 12. Secondary outcomes included prolonged and continuous tobacco abstinence rates, craving and nicotine withdrawal, and weight gain. RESULTS: The 7-day point-prevalence tobacco abstinence rates did not differ between bupropion SR and placebo at the end treatment (53.1% versus 46.4%; odds ratio (OR) 1.3; p=0.301). The 7-day point-prevalence abstinence did not differ at weeks 24 and 52. The prolonged and continuous tobacco abstinence rates did not differ at weeks 12, 24, and 52. A time-by-treatment interaction was observed in craving over time with greater decreases in the bupropion SR group. At 12 weeks, the mean (+/-S.D.) weight change from baseline among abstinent subjects was an increase of 1.7 (+/-2.9)kg for the bupropion SR group compared to 3.2 (+/-2.7)kg for placebo (p=0.005). CONCLUSIONS:Bupropion SR did not significantly increase tobacco abstinence rates among ST users, but it significantly decreased craving and weight gain over the treatment period.
Authors: Vincenzo Teneggi; Stephen T Tiffany; Lisa Squassante; Stefano Milleri; Luigi Ziviani; Alan Bye Journal: Psychopharmacology (Berl) Date: 2005-10-22 Impact factor: 4.530
Authors: Jon O Ebbert; Lowell C Dale; Christi A Patten; Ivana T Croghan; Darrell R Schroeder; Thomas P Moyer; Richard D Hurt Journal: Nicotine Tob Res Date: 2007-01 Impact factor: 4.244
Authors: Vincenzo Teneggi; Stephen T Tiffany; Lisa Squassante; Stefano Milleri; Luigi Ziviani; Alan Bye Journal: Psychopharmacology (Berl) Date: 2002-08-27 Impact factor: 4.530
Authors: Lowell C Dale; Jon O Ebbert; Darrell R Schroeder; Ivana T Croghan; Donna F Rasmussen; Judith A Trautman; Lisa Sanderson Cox; Richard D Hurt Journal: Nicotine Tob Res Date: 2002-08 Impact factor: 4.244
Authors: Thomas P Moyer; Joel R Charlson; Robert J Enger; Lowell C Dale; Jon O Ebbert; Darrell R Schroeder; Richard D Hurt Journal: Clin Chem Date: 2002-09 Impact factor: 8.327
Authors: Herbert H Severson; Brian G Danaher; Jon O Ebbert; Nora van Meter; Edward Lichtenstein; Chris Widdop; Ryann Crowley; Laura Akers; John R Seeley Journal: Nicotine Tob Res Date: 2014-08-28 Impact factor: 4.244
Authors: Jon O Ebbert; Herbert H Severson; Brian G Danaher; Darrell R Schroeder; Elbert D Glover Journal: Addict Behav Date: 2012-06-21 Impact factor: 3.913
Authors: Jon O Ebbert; Herbert H Severson; Ivana T Croghan; Brian G Danaher; Darrell R Schroeder Journal: Nicotine Tob Res Date: 2009-10-30 Impact factor: 4.244
Authors: Raka Jain; Sonali Jhanjee; Veena Jain; Tina Gupta; Swati Mittal; Patricia Goelz; E Paul Wileyto; Robert A Schnoll Journal: Nicotine Tob Res Date: 2013-08-14 Impact factor: 4.244